192 related articles for article (PubMed ID: 20157055)
21. Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.
Prestwich RJ; Viner S; Gerrard G; Patel CN; Scarsbrook AF
Br J Radiol; 2012 Oct; 85(1018):e805-13. PubMed ID: 22972977
[TBL] [Abstract][Full Text] [Related]
22. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
[TBL] [Abstract][Full Text] [Related]
24. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels.
Özdemir E; Yildirim Poyraz N; Polat SB; Turkolmez S; Ersoy R; Cakir B
Ann Nucl Med; 2014 Apr; 28(3):241-7. PubMed ID: 24379008
[TBL] [Abstract][Full Text] [Related]
26. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
27. Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis.
Mansueto M; Grimaldi A; Mangili G; Picchio M; Giovacchini G; Viganò R; Messa C; Fazio F
Eur J Cancer Care (Engl); 2009 Nov; 18(6):612-9. PubMed ID: 19549284
[TBL] [Abstract][Full Text] [Related]
28. Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging.
Abraham T; Schöder H
Semin Nucl Med; 2011 Mar; 41(2):121-38. PubMed ID: 21272686
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
30. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
Ong SC; Ng DC; Sundram FX
Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
[TBL] [Abstract][Full Text] [Related]
31. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management.
Palmedo H; Bucerius J; Joe A; Strunk H; Hortling N; Meyka S; Roedel R; Wolff M; Wardelmann E; Biersack HJ; Jaeger U
J Nucl Med; 2006 Apr; 47(4):616-24. PubMed ID: 16595495
[TBL] [Abstract][Full Text] [Related]
32. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.
Hempel JM; Kloeckner R; Krick S; Pinto Dos Santos D; Schadmand-Fischer S; Boeßert P; Bisdas S; Weber MM; Fottner C; Musholt TJ; Schreckenberger M; Miederer M
Cancer Imaging; 2016 Nov; 16(1):37. PubMed ID: 27809936
[TBL] [Abstract][Full Text] [Related]
33. What is the role of florine-18 fluorodeoxyglucose/positron emission tomography/computed tomography imaging in well-differentiated thyroid cancers with negative iodine-131 scan high thyroglobulin and normal anti-thyroglobulin levels.
Döner RK; Sager S; Görtan FA; Topuz ÖV; Akyel R; Vatankulu B; Baran A; Teksoz S; Sönmezoglu K
J Cancer Res Ther; 2016; 12(2):1010-7. PubMed ID: 27461690
[TBL] [Abstract][Full Text] [Related]
34. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid.
Suh I; Vriens MR; Guerrero MA; Griffin A; Shen WT; Duh QY; Clark OH; Kebebew E
Am J Surg; 2010 Jul; 200(1):41-6. PubMed ID: 20637335
[TBL] [Abstract][Full Text] [Related]
35. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
[No Abstract] [Full Text] [Related]
36. F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience.
Elboga U; Karaoglan H; Sahin E; Kalender E; Demir HD; Basıbuyuk M; Zeki Celen Y; Yilmaz M; Ozkaya M
Eur Rev Med Pharmacol Sci; 2015; 19(3):396-401. PubMed ID: 25720709
[TBL] [Abstract][Full Text] [Related]
37. Detection of metastatic cervical lymph nodes in recurrent papillary thyroid carcinoma: computed tomography versus positron emission tomography-computed tomography.
Lee DH; Kang WJ; Seo HS; Kim E; Kim JH; Son KR; Na DG
J Comput Assist Tomogr; 2009; 33(5):805-10. PubMed ID: 19820516
[TBL] [Abstract][Full Text] [Related]
38. The potential value of hybrid positron emission tomography/dual-source computed tomography imaging in coronary bypass surgery.
Plass A; Emmert MY; Gaemperli O; Alkadhi H; Kaufmann P; Falk V; Grünenfelder J
Heart Surg Forum; 2011 Oct; 14(5):E283-90. PubMed ID: 21997649
[TBL] [Abstract][Full Text] [Related]
39. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging?
Avram AM; Fig LM; Frey KA; Gross MD; Wong KK
J Clin Endocrinol Metab; 2013 Mar; 98(3):1163-71. PubMed ID: 23430789
[TBL] [Abstract][Full Text] [Related]
40. 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.
Iagaru A; Masamed R; Singer PA; Conti PS
Mol Imaging Biol; 2006; 8(5):309-14. PubMed ID: 16758370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
